BLTE

Healthcare

Belite Bio, Inc · Biotechnology · $6B

UQS Score — Balanced Preset
13.9
Poor

Belite Bio, Inc scores 13.9/100 using the Balanced preset.

UQS vs Healthcare Sector
BLTE
13.9
Sector avg
32.4
Quality
Weak
Moat
Weak
Growth
Weak
Risk
Strong
Valuation
Elevated

BLTE Price History

+1375.7% over 5Y

Monthly close, adjusted for stock splits and dividend reinvestment.

Return Calculator

What if I invested in Belite Bio, Inc?

$
Today it would be worth
$26,186
That's a +162% total return, or +162% annualized.

Based on Belite Bio, Inc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

Unlock Full BLTE Analysis

Sign in to unlock the detailed analysis behind the UQS Score.

  • Detailed 6-pillar UQS breakdown with exact scores
  • All 29 metrics with sector-calibrated comparisons
  • 6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
  • Watchlist tracking with score alerts
  • AI-generated investment perspectives across 6 preset views
  • Score history chart with change notifications
Analyze BLTE in Detail →

Pro Analysis

BLTE — Score History

51015202530May 25Jun 12Jun 30Jul 18Aug 5Aug 22
Score changes· 30/41 most recent
DateUQSQualityMoatGrowthRiskValueChange
Aug 22, 202613.90.06.00.082.40.0-8.1
Aug 1, 202622.00.06.018.875.336.2-0.1
Jul 25, 202622.10.06.018.875.337.0+0.1
Jul 24, 202622.00.06.018.875.336.4-0.1
Jul 23, 202622.10.06.018.875.336.7+0.1
Jul 22, 202622.00.06.018.875.336.1-0.2
Jul 21, 202622.20.06.018.875.337.30.0
Jul 17, 202622.20.06.018.875.337.70.0
Jul 16, 202622.20.06.018.875.337.9-0.1
Jul 14, 202622.30.06.018.875.338.3+0.1

BLTE — Pillar Breakdown

Quality

0.0/100 (25%)

Belite Bio, Inc currently shows below-average quality metrics, suggesting challenges with profitability.

Capital Efficiency (ROIC)Weak

How effectively capital is deployed to generate returns.

Operating ProfitabilityWeak

Ability to convert revenue into operating profit.

Net ProfitabilityWeak

Bottom-line profit as a share of revenue.

Cash GenerationWeak

Free cash flow relative to market value.

Growth

0.0/100 (20%)

Belite Bio, Inc faces growth headwinds with declining or stagnant revenue trends.

Recent Revenue TrendWeak

Revenue trajectory over the last twelve months.

EPS GrowthWeak

Year-over-year earnings per share growth.

Forward Revenue OutlookWeak

Analyst consensus for future revenue growth.

Risk

82.4/100 (15%)

Belite Bio, Inc carries minimal financial risk with conservative leverage and strong solvency.

Financial LeverageStrong

Debt levels relative to earnings capacity.

Debt/EquityStrong

Total debt relative to shareholder equity.

Current RatioStrong

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageWeak

Earnings capacity relative to interest payments.

Valuation

0.0/100 (15%)

Belite Bio, Inc appears expensively valued relative to its fundamentals and growth prospects.

Moat

6/100 (25%)

Belite Bio, Inc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BLTE.

Score Composition

Quality
0.0×25%0.0
Growth
0.0×20%0.0
Risk
82.4×15%12.4
Valuation
0.0×15%0.0
Moat
6.0×25%1.5
Total
13.9Poor

Financial Data

More Stock Analysis

How is the BLTE UQS Score Calculated?

The UQS (Unified Quality Score) for Belite Bio, Inc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Belite Bio, Inc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Belite Bio, Inc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.